Gene linked to pancreatic cancer growth, study finds

January 31, 2012 in Cancer

Gene linked to pancreatic cancer growth, study finds

Enlarge

When Kras is turned off, early stage precancerous pancreatic lesions transform into normal pancreas cells. Credit: University of Michigan Comprehensive Cancer Center

A mutant protein found in nearly all pancreatic cancers plays a role not only in the cancer's development but in its continued growth, according to a new study from University of Michigan Comprehensive Cancer Center researchers. The finding suggests a possible target for developing new ways to treat this deadly disease.

Researchers have known that mutations in the Kras gene are what cause pancreatic cancer to develop. These mutations are frequently seen in common precancerous lesions, suggesting it has an early role in pancreatic cancer.

The new study, published in the February , finds that in mice, mutant Kras also keeps the tumor growing and helps precancerous tumors grow into invasive cancer. When the researchers turned off Kras, the tumors disappeared and showed no signs of recurring.

The researchers were able to manipulate Kras in a mouse model that they designed to look at Kras at various points in pancreatic . In the , turning off Kras eliminated the tumors in mice and the pancreas tissue returned to normal, with no signs of the cancer returning. With , inactivating Kras killed off the cancer but left the pancreas with fibrous areas similar to . Tumors did not recur.

Researchers hope this finding provides the basis for future drug development.

"Right now no drugs specifically target Kras, but there are drugs that target the cellular processes downstream of Kras. We next need to figure out which of these downstream effectors of Kras are important in pancreatic cancer," says study author Marina Pasca di Magliano, Ph.D., assistant professor of surgery and of cell and developmental biology at the U-M Medical School.

Kras is also known to play a role in lung and . But it is likely the biggest player in pancreatic cancer, where more than 90 percent of all tumors have mutated Kras. Pancreatic cancer is one of the most deadly types of cancer: about 4 percent of patients are alive five years after their diagnosis. The disease is often diagnosed when surgery is not an option and it tends to be resistant to available chemotherapies.

"There is a dire need for new therapies for pancreas cancer based on a better understanding of the biology of this disease. My lab is now looking at the downstream inhibitors of Kras to try to find the best target," Pasca di Magliano says.

More information: Journal of Clinical Investigation, Vol. 122, No. 2, February 2012

Journal reference: Journal of Clinical Investigation search and more info website

Provided by University of Michigan Health System search and more info website

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

American cancer society celebrates 100 years of progress

(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.

Cancer created 5 hours ago | popularity not rated yet | comments 0

CT detects twice as many lung cancers as X-ray at initial screening exam

National Lung Screening Trial (NLST) investigators also conclude that the 20 percent reduction in lung cancer mortality with low-dose computed tomography (LDCT) versus chest X-ray (CXR) screening previously reported in the ...

Cancer created 5 hours ago | popularity not rated yet | comments 0

Research offers promising new approach to treatment of lung cancer

Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage ...

Cancer created 9 hours ago | popularity not rated yet | comments 0 | with audio podcast

Study details genes that control whether tumors adapt or die when faced with p53 activating drugs

When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die – the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even i ...

Cancer created 9 hours ago | popularity not rated yet | comments 0 | with audio podcast

Small increase in cancer risk following CT scans in childhood and adolescence

Study leader, Professor John Mathews from the University of Melbourne said this small increase in cancer risk must be weighed against the undoubted benefits from CT scans in diagnosing and monitoring disease.

Cancer created 13 hours ago | popularity not rated yet | comments 0


Slowing the aging process—only with antibiotics

Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.

Researchers complete largest genetic sequencing study of human disease

Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.

Brain can be trained in compassion, study shows

Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.

Having both migraines, depression may mean smaller brain

(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.

Novel approach for influenza vaccination shows promise in early animal testing

A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...

Enzyme-activating antibodies revealed as marker for most severe form of rheumatoid arthritis

In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe ...